Unknown

Dataset Information

0

Nonimmunogenetic Viral Capsid Carrier with Cancer Targeting Activity.


ABSTRACT: Although protein nanoparticles (PNPs) (e.g., viral capsids) capable of delivering a broad range of drug agents have shown distinctive advantages over synthetic nanomaterials, PNPs have an intrinsic drawback that hampers their clinical application, that is, potential immunogenicity. Here, a novel method for resolving the immunogenicity problem of PNPs, which is based on the genetic presentation of albumin-binding peptides (ABPs) on the surface of PNP, is reported. ABPs are inserted into the surface of a viral capsid (hepatitis B virus capsid/HBVC) while preserving the native self-assembly function of HBVC. The ABPs effectively gather human serum albumins around HBVC and significantly reduce both inflammatory response and immunoglobulin titer in live mice compared to ABP-free HBVC. Furthermore, ABP-conjugated HBVCs remain within tumors for a longer period than HBVCs conjugated to tumor cell receptor-bindingpeptides, indicating that the ABPs are also capable of enhancing tumor-targeting performance. Although applied to HBVC for proof of concept, this novel approach may provide a general platform for resolving immunogenicity and cancer-targeting problems of PNPs, which enables the development of a variety of PNP-based drug delivery carriers with high safety and efficacy.

SUBMITTER: Lee BR 

PROVIDER: S-EPMC6097151 | biostudies-literature | 2018 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

Nonimmunogenetic Viral Capsid Carrier with Cancer Targeting Activity.

Lee Bo-Ram BR   Jo Eunji E   Yoon Hong Yeol HY   Yoon Chul Joo CJ   Lee Hyo-Jung HJ   Kwon Koo Chul KC   Kim Tae Woo TW   Lee Jeewon J  

Advanced science (Weinheim, Baden-Wurttemberg, Germany) 20180627 8


Although protein nanoparticles (PNPs) (e.g., viral capsids) capable of delivering a broad range of drug agents have shown distinctive advantages over synthetic nanomaterials, PNPs have an intrinsic drawback that hampers their clinical application, that is, potential immunogenicity. Here, a novel method for resolving the immunogenicity problem of PNPs, which is based on the genetic presentation of albumin-binding peptides (ABPs) on the surface of PNP, is reported. ABPs are inserted into the surfa  ...[more]

Similar Datasets

| S-EPMC4910953 | biostudies-literature
| S-EPMC6156566 | biostudies-literature
| S-EPMC2737063 | biostudies-literature
| S-EPMC5415599 | biostudies-literature
| S-EPMC4318123 | biostudies-literature
| S-EPMC7183857 | biostudies-literature
| S-EPMC7830116 | biostudies-literature
| S-EPMC8549334 | biostudies-literature
| S-EPMC5757074 | biostudies-literature
| S-EPMC2410070 | biostudies-literature